Favipiravir permanently registered in Russia for COVID-19 treatment

(TASS) – Favipiravir, a drug used to treat COVID-19, has received permanent registration in Russia, Russian Deputy Health Minister Viktor Fisenko said on Thursday.

“Following a sped-up procedure, we have greenlit circulation of prevention drugs (vaccines), antiviral therapy drugs – Favipiravir, Remdesivir, and a drug used to mitigate a cytokine storm – Levilimab,” he said, adding that Favipiravir has received a permanent registration certificate.

Earlier, the Russian Federal Service for Surveillance in Healthcare informed that Russia had registered three drugs based on Favipiravir: Avifavir, Areplivir and Coronavir. The watchdog has not received any complaints of non-specific motor disorders during the use of the drugs.